Orient EuroPharma and Debiopharm Group™ Announce Their Partnership
News May 27, 2014
Orient EuroPharma Co., Ltd. and Debiopharm Group™ have jointly announced the signature of a distribution agreement for the commercialization and promotion of Pamorelin® in South East Asia.
Orient EuroPharma and Debiopharm have announced the launch of Pamorelin® in Singapore for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer.
Under the terms of the agreement, Orient EuroPharma acquires exclusive marketing and sales rights for Pamorelin® in Singapore, its first launch territory. The product is exported in finished bulk from Debiopharm Research and Manufacturing SA to Orient EuroPharma. Pamorelin® will be made available primarily to urologists and oncologists across Singapore.
Mr.JP. Chang, President of Pharmaceutical Business Unit, Orient EuroPharma said that “it is great to cooperate with Debiopharm Group™ for introducing the new drug to South East Asian territories. Orient EuroPharma owns strong connections and an experienced team in the Oncology field; this partnership will provide another therapy option for physicians to treat prostate cancer patients”.
“This collaboration opens up an important new market for our backbone therapy of advanced prostate cancer (locally advanced and metastatic)” said Thierry Mauvernay, Delegate of the Board, Debiopharm Group. “After successful launch in 74 countries, we look forward to bringing Pamorelin® to several South East Asian markets, together with Orient EuroPharma”.
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Targeting Epigenetic Proteins to Prevent Breast CancerNews
Researchers have discovered that epigenetic proteins promote the proliferation of mammary gland stem cells in response to the sex hormone progesterone. The study suggests that inhibiting these proteins with drugs could prevent the development of breast cancer in women at high risk of the disease.READ MORE
Compound as Effective as FDA-Approved Drugs Against Life-Threatening InfectionsNews
Purdue University researchers have identified a new compound that in preliminary testing has shown itself to be as effective as antibiotics approved by the Food and Drug Administration to treat life-threatening infections while also appearing to be less susceptible to bacterial resistance.READ MORE